Cyclic Glycyl Proline Compounds for Autism Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Autism Spectrum Disorders (ASDs) and Neurodevelopmental Disorders (NDDs) are primarily symptomatic and lack effective therapies, with patient care limited to managing symptoms through social and behavioral interventions, and there is no established treatment for normalizing abnormal social behavior or addressing cognitive impairments.
Innovation Solution
The development of novel bicyclic compounds, specifically cyclic Glycyl Proline (cGP) and its analogs, such as cyclic Glycyl-2-Allyl Proline (cG-2-AllylP), which exhibit neuroprotective and neuroregenerative properties, are used to treat ASDs and NDDs by normalizing abnormal social behavior, reducing anxiety, hyperactivity, and cognitive impairments, and are administered to effectively treat symptoms in both animal models and humans.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If symptomatic treatments and behavioral interventions are used for ASDs and NDDs, then symptom management is provided, but effective therapy for underlying causes and normalization of abnormal social behavior is not achieved
Solution Approach 1:
The patent introduces bicyclic compounds as intermediary substances that mediate between the underlying neurological causes of ASDs/NDDs and the observable symptoms. These compounds act as neuroprotective agents that address root causes while producing therapeutic effects on multiple symptoms simultaneously, bridging the gap between symptom management and effective therapy.
Solution Approach 2:
The bicyclic compounds exhibit multi-functionality by simultaneously addressing multiple aspects of ASDs and NDDs including neuroprotection, normalization of social behavior, reduction of anxiety and hyperactivity, and improvement of cognitive impairments. This single agent performs multiple therapeutic functions that were previously requiring separate interventions.
2Ease of operation
If current symptomatic treatments are used, then some symptom management is provided, but normalization of abnormal social behavior and cognitive impairments is not achieved
Solution Approach 1:
The bicyclic compounds serve as universal therapeutic agents that simultaneously target multiple pathological features of ASDs and NDDs. A single compound administration provides neuroprotection, behavioral normalization, and cognitive improvement, simplifying the treatment approach while enhancing therapeutic effectiveness through multi-target action.
3Reliability
If novel bicyclic compounds are developed for treating ASDs and NDDs, then effective therapy for underlying causes is provided, but treatment complexity increases
Solution Approach 1:
The bicyclic compounds consolidate multiple therapeutic functions into a single agent, reducing treatment complexity despite addressing multiple underlying causes. The universal applicability of these compounds across different manifestations of ASDs and NDDs simplifies the overall treatment regimen while maintaining high therapeutic effectiveness.
Data Source
AI summary
Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat symptoms of Autistic Disorder or Autism, as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.